Life Sciences

  • February 02, 2024

    USPTO Slams Lundbeck's PTSD Drug Patent Term Suit

    The U.S. Patent and Trademark Office is going for an early win in Virginia federal court where Danish drugmaker H. Lundbeck A/S is seeking to extend the life of a patent for a PTSD drug by three months, calling the case straightforward.

  • February 02, 2024

    4th Circ. Vacates Va. Doctor's Conviction In Pill Mill Scheme

    The Fourth Circuit on Friday called for a new trial of a doctor who was sentenced to 40 years in prison over his opioid-prescription practices, finding that the jury was erroneously instructed during his trial.

  • February 02, 2024

    Harvard Prof. Slams Study Showing IQ Gains From Fluoride

    A Harvard epidemiologist testifying Friday in a high-stakes bench trial over fluoridated water's risks criticized a study cited by the government that found fluoride exposure increases IQ by 24 points, saying the results "don't make sense," are "beyond the imagination" and must be based on erroneous data.

  • February 02, 2024

    ABA Chides 5th Circ. At High Court Over Mifepristone Ruling

    The American Bar Association on Friday urged the U.S. Supreme Court to undo a Fifth Circuit opinion affirming limits on access to the abortion medication mifepristone, saying it doesn't typically weigh in on such cases, but asserting the appeals court wrongly "second-guessed" the Food and Drug Administration.

  • February 02, 2024

    Judge Tosses Involuntary Releases In Amyris Ch. 11 Plan

    A Delaware bankruptcy judge on Friday struck down biotechnology company Amyris Inc.'s plan to shield executives and others from liability using nonconsensual releases as part of its Chapter 11 plan, finding that Amyris can reorganize without relying on the controversial mechanism.

  • February 02, 2024

    Drugmaker Endo Wants To Extend Opioid Suit Pause

    Endo has asked a New York bankruptcy judge to pause the opioid litigation leveled against it for five more months, asserting that the pharmaceutical company made "wide-ranging progress" in its Chapter 11 case and expects to have a reorganization plan confirmed by March.

  • February 02, 2024

    ACLU Atty On How To Protect Civil Liberties In The AI Era

    Because artificial intelligence and algorithmic systems often operate in the shadows, there's a new need for legislation, regulation and enforcement to ensure the technology doesn't undercut civil liberties by engaging in discrimination in housing, education or employment, according to Cody Venzke, senior policy counsel for the American Civil Liberties Union.

  • February 02, 2024

    Families New To Tylenol MDL Cite Expert To Avoid Dismissal

    A dozen parents and children who allege that prenatal exposure to acetaminophen caused ADHD have urged a federal judge to keep their lawsuits alive, contending that they aren't bound by an earlier ruling that barred every expert witness set to testify for plaintiffs in similar cases.

  • February 02, 2024

    Latham Led Firms In January IPOs As New Listings Pick Up

    Latham & Watkins LLP assumed work on more initial public offerings than any other law firm in January, steering five IPOs for companies and underwriters during a month that saw a rise in new listings that could portend additional momentum beyond February.

  • February 02, 2024

    Ascension Says Medical Queries Don't Breach Genetic Privacy

    Questions about family medical history raised during a hospital job interview don't implicate an Illinois genetic privacy law, healthcare giant Ascension Health has told a Missouri federal court.

  • February 02, 2024

    Pennsylvania AG's Clout In Opioid Deal Likely Has Wide Reach

    A Pennsylvania court's ruling that the attorney general had the power to overrule local district attorneys' objections to a big opioid settlement could affect the prosecutors' power dynamic beyond the painkiller litigation, overshadowing other areas where they could share jurisdiction or clash over politically sensitive issues, attorneys told Law360.

  • February 02, 2024

    McCarter & English To Face Revised Biotech Malpractice Suit

    A New Jersey state judge on Friday permitted a biopharmaceutical company to amend its malpractice suit against McCarter & English LLP to add new claims and avenues to collect damages, finding the changes were "sufficiently pled" and would not be prejudicial to the firm.

  • February 02, 2024

    DLA Piper Hires McDermott's FDA Practice Leader In DC

    DLA Piper LLP has hired the leader of McDermott Will & Emery's U.S. Food and Drug Administration-focused practice as the new co-chair of their own FDA practice, according to a Thursday announcement.

  • February 02, 2024

    UK Regulator Examining Thermo Fisher's $3.1B Olink Buy

    The U.K.'s Competition and Markets Authority said Friday that it is looking into American biotechnology company Thermo Fisher Scientific's planned $3.1 billion purchase of Swedish biotech business Olink to determine whether it will result in reduced competition.

  • February 02, 2024

    2 Biotech Firms Tap Thawing IPO Market To Raise $239M Total

    Shares of drug developers Fractyl Health Inc. and Alto Neuroscience Inc. began trading with mixed results on Friday after the life sciences startups raised nearly $239 million combined in initial public offerings, guided by three law firms.

  • February 01, 2024

    Ex-FDA Leaders Urge High Court To Nix Mifepristone Ruling

    Seven former commissioners and acting commissioners of the U.S. Food and Drug Administration told the U.S. Supreme Court on Thursday that a Fifth Circuit decision reinstating some restrictions on mifepristone, a drug used to end early pregnancies and manage miscarriages, threatens the nation's drug approval process.

  • February 01, 2024

    Harvard Professor Testifies Fluoride Is 'Definitely' Neurotoxic

    A Harvard epidemiologist testified in a high-stakes bench trial over environmental groups' efforts to get the U.S. Environmental Protection Agency to ban fluoride in 200 million Americans' drinking water that there is "definitely a causal relationship" between fluoride exposure and neurotoxicity, even at low exposure levels.

  • February 01, 2024

    Stimwave Trustee Seeks Stay Of Perryman Actions In Ch. 11

    Stimwave Technologies' liquidating trustee asked a Delaware judge to pause almost all the adversary suits by the company's ex-CEO and her family until the court can mull its objections to the claims.

  • February 01, 2024

    Pharma Hikma Reaches $150M Opioid Settlement With States

    Hikma Pharmaceuticals and several attorneys general announced a $150 million agreement in principle on Thursday resolving cases brought by a group of states and localities alleging the company fueled the opioid crisis by failing to report suspicious opioid orders from potentially illegal distributors.

  • February 01, 2024

    Assa Abloy Nabs PTAB Win Against Biometric Security Patent

    The Patent Trial and Appeal Board has invalidated all claims in a CPC Patent Technologies Pty Ltd. biometric security patent that was attacked in a pair of challenges by Assa Abloy AB.

  • February 01, 2024

    Denver Man Accused Of Romancing Women Into $121K Scam

    A Denver resident scammed at least $121,000 from women he met on dating apps and at gyms by promising massive returns on investments in a fake medical treatment project, according to a lawsuit filed in state court by Colorado's securities regulator on Wednesday.

  • February 01, 2024

    Bankrupt Pharma Co. Impel Gets OK For $17.5M Sale

    Migraine-drug maker Impel Pharmaceuticals can proceed with its sale to JN Bidco LLC, which had made a $17.5 million stalking horse bid, U.S. Bankruptcy Judge Stacey G. Jernigan said at a hearing Thursday in a Texas bankruptcy court.

  • February 01, 2024

    Conn. Supreme Court Snapshot: Sleepy Juror, Surprise Billing

    A gang member's murder conviction should be overturned because a juror was caught sleeping and the judge took no action to determine if he was still competent to serve, according to an appeal that the Connecticut Supreme Court will hear in its upcoming term. Here are three cases to watch as the term gets started Monday.

  • February 01, 2024

    NJ Says Constitution Doesn't Protect Medical Aid In Dying

    New Jersey's attorney general has asked a Garden State federal court to dismiss a lawsuit alleging a residency requirement in the state's 2019 law allowing terminally ill patients to request life-ending medications violates the U.S. Constitution.

  • February 01, 2024

    Life Sciences VC Firm Seroba Closes $134M Fund

    Seroba, a European life sciences venture capital firm, said Thursday it has closed a new fund focused on early-stage life sciences companies at €123 million ($134 million).

Expert Analysis

  • Perils Of Incorporation By Reference At The Federal Circuit

    Author Photo

    The Federal Circuit's recent decision backing a Patent Trial and Appeal Board ruling against Medtronic illustrates the perils of arguments through incorporation by reference, which can result in waiver of arguments and an adverse decision on appeal, says Ryan Hagglund at Loeb & Loeb.

  • Series

    Performing Music Makes Me A Better Lawyer

    Author Photo

    The discipline of performing live music has directly and positively influenced my effectiveness as a litigator — serving as a reminder that practice, intuition and team building are all important elements of a successful law practice, says Jeff Wakolbinger at Bryan Cave.

  • 'Patient' Definition Ruling Raises Discount Drug Questions

    Author Photo

    A South Carolina federal court's recent decision in Genesis Health Care v. Becerra supports a broader definition of a "patient" eligible to receive discounted drugs under the Section 340B program, but raises a host of novel questions regarding how the decision will affect covered entities and enforcement actions, say attorneys at McDermott.

  • Breaking Down High Court's New Code Of Conduct

    Author Photo

    The U.S. Supreme Court recently adopted its first-ever code of conduct, and counsel will need to work closely with clients in navigating its provisions, from gift-giving to recusal bids, say Phillip Gordon and Mateo Forero at Holtzman Vogel.

  • How Purdue High Court Case Will Shape Ch. 11 Mass Injury

    Author Photo

    The U.S. Supreme Court's recent arguments in Harrington v. Purdue Pharma, addressing the authority of bankruptcy courts to approve nonconsensual third-party releases in Chapter 11 settlement plans, highlight the case's wide-ranging implications for how mass injury cases get resolved in bankruptcy proceedings, says George Singer at Holland & Hart.

  • Opinion

    Legal Profession Gender Parity Requires Equal Parental Leave

    Author Photo

    To truly foster equity in the legal profession and to promote attorney retention, workplaces need to better support all parents, regardless of gender — starting by offering equal and robust parental leave to both birthing and non-birthing parents, says Ali Spindler at Irwin Fritchie.

  • Managing ANDA Venue Issues As Del. And NJ Filings Rise

    Author Photo

    Delaware and New Jersey have prevailed as the primary forum for pharmaceutical litigation as more generic companies file abbreviated new drug applications, but this venue scheme presents traps for the unwary, and legislation may still be necessary to ensure fairness and predictability, say Timothy Cook and Kevin Yurkerwich at WilmerHale.

  • Series

    Writing Thriller Novels Makes Me A Better Lawyer

    Author Photo

    Authoring several thriller novels has enriched my work by providing a fresh perspective on my privacy practice, expanding my knowledge, and keeping me alert to the next wave of issues in an increasingly complex space — a reminder to all lawyers that extracurricular activities can help sharpen professional instincts, says Reece Hirsch at Morgan Lewis.

  • What Lawyers Must Know About Calif. State Bar's AI Guidance

    Author Photo

    Initial recommendations from the State Bar of California regarding use of generative artificial intelligence by lawyers have the potential to become a useful set of guidelines in the industry, covering confidentiality, supervision and training, communications, discrimination and more, say attorneys at Debevoise.

  • Industry Must Elevate Native American Women Attys' Stories

    Author Photo

    The American Bar Association's recent research study into Native American women attorneys' experiences in the legal industry reveals the glacial pace of progress, and should inform efforts to amplify Native voices in the field, says Mary Smith, president of the ABA.

  • The Fed. Circ. In Nov.: Factual Support And Appellate Standing

    The Federal Circuit's recent Allgenesis Biotherapeutics v. Cloud Break Therapeutics decision shows that appellate standing requires specific factual support, underscoring the necessary requirements for a patent challenger in an appeal from an inter partes review at the U.S. Patent and Trademark Office, say Jeremiah Helm and Sean Murray at Knobbe Martens.

  • White House Activity Is A Band-Aid For Regulating AI In Health

    Author Photo

    In the medium term, recent White House actions will have a greater impact on AI in the health care industry than Congress' sluggish efforts to regulate it, but ultimately legislation of AI's development and use in the health space will fall to Congress, say Wendell Bartnick and Vanessa Perumal at Reed Smith.

  • Understanding Discovery Obligations In Era Of Generative AI

    Excerpt from Practical Guidance
    Author Photo

    Attorneys and businesses must adapt to the unique discovery challenges presented by generative artificial intelligence, such as chatbot content and prompts, while upholding the principles of fairness, transparency and compliance with legal obligations in federal civil litigation, say attorneys at King & Spalding.

  • Kochava Ruling May Hint At Next Privacy Class Action Wave

    Author Photo

    The Southern District of California's recent ruling in Greenley v. Kochava and increasing complaints alleging that a consumer website is an illegal “pen register” due to the use of third-party marketing software tools foreshadow a new theory of liability for plaintiffs in privacy litigation, say attorneys at Crowell & Moring.

  • Forecasting The Impact Of High Court Debit Card Rule Case

    Author Photo

    John Delionado and Aidan Gross at Hunton consider how the U.S. Supreme Court's forthcoming ruling in a retailer's suit challenging a Federal Reserve rule on debit card swipe fees could affect agency regulations both new and old, as well as the businesses that might seek to challenge them.

Want to publish in Law360?


Submit an idea

Have a news tip?


Contact us here
Can't find the article you're looking for? Click here to search the Life Sciences archive.
Hello! I'm Law360's automated support bot.

How can I help you today?

For example, you can type:
  • I forgot my password
  • I took a free trial but didn't get a verification email
  • How do I sign up for a newsletter?
Ask a question!